EU/3/08/588: Orphan designation for the treatment of thrombotic thrombocytopenic purpura

Recombinant human ADAMTS-13

Table of contents


On 3 December 2008, orphan designation (EU/3/08/588) was granted by the European Commission to Baxter AG, Austria, for recombinant human ADAMTS-13 for the treatment of thrombotic thrombocytopenic purpura.


Key facts

Active substance
Recombinant human ADAMTS-13
Intended use
Treatment of thrombotic thrombocytopenic purpura
Orphan designation status
EU designation number
Date of designation

Takeda Manufacturing Austria AG
Industriestrasse 67
1220 Vienna

Update history

February 2023The sponsorship was transferred from Baxalta Innovations GmbH, Austria to Takeda Manufacturing Austria AG.
April 2016The sponsorship was transferred to Baxalta Innovations GmbH, Austria. 

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating